Cool work coming out of Adrian Isaacs Lab from former Miller Lab graduate student Alex Cammack. Can’t wait to dive into the data!

Thank you The Mitchell and Friends Foundation for your generous support! We look forward to working with you on this exciting project to develop a potential treatment for Mitchell Syndrome!

neurology.wustl.edu/medical-advanc…

Huge congratulations to Dr. Miller on being elected to the National Academy of Medicine! We’re lucky to have you at the helm!

Congratulations, Alex! We look forward to seeing more of your exciting and important work!

.Tim Miller This Is Your Life! Happy to host a virtual reunion of Miller Lab alumni to celebrate the FDA approval of #tofersen for SOD1 #ALS . Congrats to Tim and everyone involved!

BREAKING: the FDA has approved a new drug called toferson for a rare form of ALS caused by mutations in the gene SOD1. #WashUMed researcher Miller Lab, MD, PhD, led the international clinical trials. ALS Center Wash U Biogen

medicine.wustl.edu/news/drug-for-…

New SOD1 #ALS drug candidate, #tofersen , is up for review by an FDA Advisory Committee on Wednesday, March 22nd from 9:15 am - 6 pm EST. You can watch the meeting virtually here: youtube.com/live/K0k6Jfcc5…

Exciting news! Well deserved honor for Tim Miller and colleagues!

“They are exceptional change makers.'

Neuroscience majors Sam Norwitz and Ephraim Oyetunji of #WashU23 were finalists for the Rhodes Scholarship, one of the world’s most prestigious academic honors, to study at the University of Oxford in England. bit.ly/3trNygE

Read our latest paper out in Nature Communications on genotype-phenotype correlations in SOD1- #ALS . This is the largest study of its kind for #SOD1 variants. Great work led by Sarah Opie-Martin and Alfredo Iacoangeli at King's College London !

nature.com/articles/s4146…

Delighted to share a major step forward in treating #ALS . Published results for ASO therapy #Tofersen for #SOD1 ALS medicine.wustl.edu/news/investiga… Tremendous thank you to the trial participants, their caregivers, and site personnel.

Congratulations to Ephraim Oyetunji who was just selected as a 2022 Barry M. Goldwater Scholar! Well deserved recognition!

I've been writing research articles for over 10 years now and one of the hardest parts is writing consistently and efficiently without procrastinating. I'm going to share some of my tips here 🧵 1/10